Liposomes represent a mature, robust technology for the delivery of therapeutic drugs – small molecules, DNA, proteins – owing to their ability to mimic the physical and chemical characteristics of living cells. The ability to control their assembly enables biophysical control of the interaction between liposomes and encapsulated material.
Though liposomes have been approved by the FDA for clinical use, in recent years the emergence of new liposome-based systems that enable the delivery of target material to specific organelles, as well as allow for more efficient function such as skin penetration, has added attractive new knowledge to the field.
Liposome-based encapsulation is an active area of growing interest at Akron, and research and development efforts in that area are currently ongoing.
Last week, Akron’s Claudia Zylberberg and Sandro Matosevic published a review paper titled “Pharmaceutical liposomal drug delivery: a review of new delivery systems and a look at the regulatory landscape” in the journal Drug Delivery.
The paper focuses on new delivery systems that have emerged in the last few years – including ethosomes, transferosomes, pharmacosomes and more – as extensions of traditional liposomes, and discusses recent clinical efforts in the commercial approval for these technologies. This review represents a unique example of a recent peer-reviewed manuscript that focuses on new liposome-based delivery technologies which have emerged in recent years. A focus on recent FDA guidelines provides additional relevant information on the clinical relevance of these systems.
The paper is accessible here.